Collectively, these data indicated that IFX treatment could downregulate intestinal mucosa and PBMC lnc-ITSN1-2 in response CD patients, which implied that the change of lnc-ITSN1-2 correlated with CD treatment efficacy. The gene discussed is ITSN1; the disease is Cowden disease.